Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-149-1 | CAS number: 103-83-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Developmental toxicity / teratogenicity
Administrative data
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: guideline study under GLP conditions
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 013
- Report date:
- 2013
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 414 (Prenatal Developmental Toxicity Study)
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- Benzyldimethylamine
- EC Number:
- 203-149-1
- EC Name:
- Benzyldimethylamine
- Cas Number:
- 103-83-3
- Molecular formula:
- C9H13N
- IUPAC Name:
- benzyldimethylamine
- Test material form:
- other: liquid
- Details on test material:
- content: > 99 %
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Age at study initiation: young-adult (no further data)
- Weight at study initiation: 197-318 g
- Housing: individually
- Diet ad libitum
- Water ad libitum
- Acclimation period: 1 day
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22
- Humidity (%): 30 to 70
- Air changes (per hr): 15
- Photoperiod (hrs dark / hrs light): 12 / 12
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- arachis oil
- Details on exposure:
- The test item was administered by gavage to three groups of twenty-four time mated rats between days 5 and 19 of gestation . A further group of twenty-fourtime mated females was exposed to the vehicle only to serve as a control. All females were terminated on day 20 of gestation.
- Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- The test item formulations were analyzed for concentration, stability (days 1, 4,and 10) and homogenicity by the test facility
- Details on mating procedure:
- no data
- Duration of treatment / exposure:
- gestation day 5 to gestation day 19 (14 days)
- Frequency of treatment:
- once daily
- Duration of test:
- gestation day 5 to gestation day 20
- No. of animals per sex per dose:
- 24 females/dose
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- Dose selection is based on the results of the preliminary study:
8 time mated females received 0, 50, 100 and 200 mg/kg bw/day test item diluted in arachis oil between gestation day 5 and day 19. Due to early termination of one female , clinical signs of toxicity and actual body weight loss the highest dose was reduced to 150 mg/kg bw on day 5 or day 6 of gestation. The NOAEL in this preliminary study was considered to be 100 mg/kg bw/day.
For the main developmental study a dosage sequence of 0, 35, 75 and 150 mg/kg bw/dy was recommended.
Examinations
- Maternal examinations:
- mortality: twice daily
clinical observations: once daily
body weight determination on day 3, 5, 6, 7, 8, 11, 14, 17, and 20 of gestation
food consuption determination on day 3, 5, 8, 11, 14, 17 and 20 of gestation
water consumption daily inspected - Ovaries and uterine content:
- uterine / implantation data:
pregnancy status, number of corpora lutea, gravid uterus weight
number, status and intra-uterine position of implantations - Fetal examinations:
- external foetal abnormalities, foetal weight foetal sex, placental weight, skeletal and visceral foetal abnormalities
- Statistics:
- parametric analysis of variance followed by pairwise comparison or non parametirc methods were used
- Indices:
- pre-implantation loss, post-implantation loss, % male foetuses for determination of sex ratio, fertility index, gestation index
Results and discussion
Results: maternal animals
Maternal developmental toxicity
- Details on maternal toxic effects:
- Maternal toxic effects:yes
Details on maternal toxic effects:
----Mortality
There were no unsheduled deaths
----Clinical signs:
from 35 mg/kg bw/day unspecific signs:
-some females showed increased salivation from day 13 earliest
-some females showed noisy respiration or decreased respiration
----Body weight
--at 35 and 75 mg/kg bw/day:
Body weight development was comparable to control animals
-- at 150 mg/kg bw/day
Females showed a marked reduction in body weight gain throughout the the treatment period
Compared to the control animals body weight gain was reduced by 41 %
----Food consumption
at 150 mg/kg bw/day
females showed a reduction (-13 %) in overall food consumption
----Water consumption
No adverse effects were detected
----Post mortem studies
No treatment related macroscopic abnormalities were detected.
----Fertility index and gestation index
was about 100 % in all dose groups including controls
----Number of corpora lutea and gravid uterus weight
at 150 mg/kg bw/day significantly reduced .
Group mean litter value:
number of corpora lutea
at 150 mg/kg bw/day: 12.2 (p<0.01); at 75 mg/kg bw/day: 14.5; at 35 mg/kg/bw/day: 14.9 versus control: 14.7
This intergroup difference was considered to be incidental and unrelatated to treatment due to ovulation and mating occuring prior to the administration of the test substance
Effect levels (maternal animals)
open allclose all
- Dose descriptor:
- NOAEL
- Effect level:
- 75 mg/kg bw/day
- Basis for effect level:
- other: maternal toxicity
- Dose descriptor:
- NOEL
- Effect level:
- 150 mg/kg bw/day
- Basis for effect level:
- other: developmental toxicity
- Dose descriptor:
- NOEL
- Effect level:
- 150 mg/kg bw/day
- Basis for effect level:
- other: other:
Results (fetuses)
- Details on embryotoxic / teratogenic effects:
- Embryotoxic / teratogenic effects:no effects
Details on embryotoxic / teratogenic effects:
No treatment related effects were detected in
----foetal viability (male and female), or in
----foetal weights (male and females), or in
----growth and development.
Sex ratio was in the normal range
Fetal examination:
No treatment related effects were detected on fetal external findings.
No treatment-related effects were detected on skeletal development (including osseous and cartilaginous tissue) amd
none in the type and incidence of skeletal or visceral findings in fetuses from females treated with 150, 75 or 35 mg/kg bw/day.
A teratogenic effect of treatment was not evident up to and including the highest dose level (150 mg/kg bw/day)
Effect levels (fetuses)
open allclose all
- Dose descriptor:
- NOEL
- Effect level:
- 150 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: developmental toxicity
- Dose descriptor:
- NOEL
- Effect level:
- 150 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: other:
Fetal abnormalities
- Abnormalities:
- no effects observed
Overall developmental toxicity
- Developmental effects observed:
- not specified
Applicant's summary and conclusion
- Conclusions:
- In conclusion, despite general toxicity (body weight reduction) in female rats at 150 mg/kg bw/day there is no evidence that the substance shows developmental toxicity.
- Executive summary:
According to OECD TG 414 and under GLP conditions pregnant female rats received orally 0, 35, 75 and 150 mg/kg bw/day by gavage on gestation day 5 -19. All females were terminated on gestation day 20 and cesarian section was performed to evaluate the developing organism.
At the highest dose of 150 mg/kg bw/day females gained markedly less body weight (by 41 % compared to control) and a reduction (-13 %) in overall food consumption. Fertility index and gestation index was calculated to be 100 % in all treated animals including control animals. Post mortem, no macroscopic abnormalities were observed. Thus, due to the reduced weight gain at 150 mg/kg bw/day the NOAEL (maternal toxicity) is considered 75 mg/kg bw/day.
No treatment related effects were detected in foetal viability (male and female), or in foetal weights (male and females), or in growth and development. Sex ratio was in the normal range. No treatment related effects were detected on fetal external findings.
No treatment-related effects were detected on skeletal development (including osseous and cartilaginous tissue) and none in the type and incidence of skeletal or visceral findings in fetuses from females treated with 150, 75 or 35 mg/kg bw/day.
A teratogenic effect of treatment was not evident up to and including the highest dose level (150 mg/kg bw/day)
Thus, the NOEL (No Adverse Effect Level) for reproductive and developmental toxicity isconsidered to be 150 mg/kg bw/day
In conclusion, despite general toxicity (body weight reduction) in female rats at 150 mg/kg bw/day there is no evidence that the substance shows developmental toxicity.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

EU Privacy Disclaimer
På den här webbplatsen används kakor. Syftet är att optimera din upplevelse av den.